Anti-phospholipid antibody mediated fetal loss: still an open question from a pathogenic point of view

Abstract

Antiphospholipid antibodies (aPL) are associated with recurrent miscarriages and pregnancy complications, however their pathogenic mechanisms are still matter of research. Thrombotic events at the placental level cannot explain all of the clinical manifestations. It has been suggested that aPL may be responsible for a local acute inflammatory response mediated by complement activation and neutrophil infiltration eventually leading to fetal loss. However histological and immunohistological studies on human placental samples do support such a mechanism only in part and with no any clear relationship with the pregnancy outcome. A direct effect of aPL on both maternal and fetal placental tissues has been reported through the reactivity of the antibodies with beta2 glycoprotein I (β2GPI) expressed on the cell membranes. These events do not require an inflammatory response and can be in part related to the inhibition of growth factors favouring a physiological placentation. Understanding the different pathogenic mechanisms of aPL-associated miscarriages may help in improving our therapeutic approach particularly in recurrent cases not responsive to the usual treatment. Lupus (2010) 19, 453—456.

Keywords

antiphospholipid antibodies fetal loss complement growth factor placenta

Get full access to this article

View all access options for this article.

References

Pierangeli SS , Chen PP , Raschi E. , et al. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost 2008; 34: 236-250.

Rand JH , Wu XX , Guller S. , et al. Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am J Obstet Gynecol 1994; 171: 1566-1572.

Park AL Placental pathology in antiphospholipid syndrome. In: Khamashta MA (ed.), Hughes’ syndrome, 2nd edn. London: Springer ; 2006. p. 362-374.

Gerosa M. , De Angelis V. , Trespidi L. , et al. Complement involvement in antiphospholipid antibody-mediated placental damage: prospective study in APS pregnant women. Ann Rheum Dis 2009; 68(Suppl 3): 210.

Chaouat G.

The Th1/Th2 paradigm: still important in pregnancy?

Semin Immunopathol 2007; 29: 95-113.

Girardi G.

Role of tissue factor in the maternal immunological attack of the embryo in the antiphospholipid syndrome

Clin Rev Allergy Immunol 2009 Nov. 17; [Epub ahead of print].

Martinez de la Torre Y. , Buracchi C. , Borroni EM , et al. Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6. Proc Natl Acad Sci U S A 2007; 104: 2319-2324.

Girardi G, Redecha P. , Salmon J. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004; 10: 1222-1226.

Cowchock FS , Reece EA , Balaban D. , Branch DW , Plouffe L. Repeated fetal losses associated with antiphospholipid antibodies: A collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol 1992; 166: 1318-1323.

10.

Shamonki JM , Salmon JE , Hyjek E. , Baergen RN Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol 2007; 196: 167.e1-5.

11.

Meroni PL , Gerosa M. , Raschi E. , Scurati S. , Grossi C. , Borghi MO Updating on the pathogenic mechanisms 5 of the antiphospholipid antibodies-associated pregnancy loss. Clin Rev Allergy Immunol 2008 ; 34: 332-337.

12.

Francis J. , Rai R. , Sebire NJ , et al. Impaired expression of endometrial differentiation markers and complement regulatory proteins in patients with recurrent pregnancy loss associated with antiphospholipid syndrome. Mol Hum Reprod 2006; 12: 435-442.

13.

Borghi MO , Raschi E. , Broggini V. , et al. Antiphospholipid antibody reactivity with human decidual cells: an additional mechanism of pregnancy complications in APS and a potential target for innovative therapeutic intervention. Ann Rheum Dis 2009; 68(Suppl 3): 109.

14.

Di Simone N. , Marana R. , Castellani R. , et al. Decreased heparin-binding growth factor expression as a new pathogenic mechanism of the antiphospholipid-mediated defective placentation. Arthritis Rheum (in press).

15.

Vega-Ostertag M. , Liu X. , Henderson V. , Pierangeli SS A peptide that mimics the Vth region of beta-2-glycoprotein I reverses antiphospholipid-mediated thrombosis in mice. Lupus 2006; 15: 358-365.

16.

Martinez de la Torre Y. , Raschi E. , Borghi MO , et al. Pregnant naïve mice are protected from aPL-induced foetal loss by the injection of a synthetic peptide (TIFI) mimicking the β2GPI PL-binding site. Arthritis Rheum 2008; 58(Suppl): S404.